Clinical Trials Logo

GVHD, Acute clinical trials

View clinical trials related to GVHD, Acute.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04118075 Completed - GVHD, Acute Clinical Trials

PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

All patients received Flu-BU-VP16 as myeloablative conditioning followed by cyclophosphamide (D+3 and +4) and subsequent tacrolimus. For patients with unrelated or haplo-donor received low-dose ATG at Day +15.

NCT ID: NCT03763318 Completed - GVHD Clinical Trials

A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD

EQUATE
Start date: July 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of EQ001 in subjects with Acute Graft Versus Host Disease (aGVHD).

NCT ID: NCT03605927 Completed - GVHD Clinical Trials

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

Start date: February 15, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004 to standard of care Sirolimus (SIR)-based immune suppression.